ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Threonine in Coronary Artery Disease: Insights From Metabolic Syndrome Amino Acid Profiling.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Metabolic syndrome (MeS) amplifies cardiovascular risk, but molecular markers that distinguish between MeS and coronary artery disease (CAD) remain limited. The aim of this study was to determine whether targeted amino acid profiling can identify CAD-specific signals independent of MeS and suggest translational biomarkers for risk stratification. MATERIAL AND METHODS In a prospective single-center cohort, we quantified 48 serum amino acids by liquid chromatography-tandem mass spectrometry in 65 fasting adults undergoing planned evaluation for chronic coronary syndrome. Quality control comprised blanks, reference sera, internal standards, and retention-time monitoring. Coronary artery disease was adjudicated angiographically in a reference hemodynamic center. Participants were grouped by metabolic syndrome (n=25) versus controls (n=40) and further stratified by CAD status. Group differences were assessed nonparametrically (2-sided alpha=0.05). RESULTS The MeS group exhibited a distinct signature versus controls, with lower histidine, ethanolamine, and tryptophan, and higher cystine and proline (all P≤0.03). The CAD prevalence was 60% in MeS versus 35% in controls (P=0.051). Across MeS strata, threonine was associated most robustly with CAD: concentrations were higher in angiography-confirmed CAD irrespective of MeS, with significant pairwise differences among noMeS+noCAD, MeS+noCAD, noMeS+CAD, and MeS+CAD groups (P=0.03-0.048). Other MeS-linked amino acids were not consistently associated with CAD. Multivariable adjustment was not performed due to the limited sample size. CONCLUSIONS Targeted amino-acid profiling revealed redox- and immune-linked perturbations in MeS and identified threonine as a potential exploratory signal of CAD independent of MeS in our exploratory, limited-sample-size study. If validated, threonine may refine CAD risk stratification beyond traditional risk factors and MeS-related metabolic changes and inform mechanistic studies of amino-acid metabolism in atherogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.